| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We have explored practical biomarkers for overall evaluation of metabolic disease risks, focusing on the inflammation-related biomarkers that have been suggested to be involved in the onset and development of metabolic diseases. The principal component 1 score from metabolic syndrome diagnostic parameters was strongly associated with not only plasma IL-1β and IL-6 levels, but also with plasma γ-GTP and ALT levels. Follow-up of the health checkup participants for 5 years revealed that the changes in blood HbA1c levels were positively associated with the initial plasma levels of γ-GTP and ALT. The results of this study suggest that plasma γ-GTP and ALT levels in combination, are the valid and practical biomarkers for prediction of metabolic disease risks.
|
